We could not find any results for:
Make sure your spelling is correct or try broadening your search.
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, โMomentaโ or the โCompanyโ), a biotechnology company focused on discovering and developing novel...
Chesapeake Utilities to Join S&P SmallCap 600 PR Newswire NEW YORK, Sept. 25, 2020 NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Chesapeake Utilities Corp (NYSE:CPK) will replace Momenta...
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals,ย Inc. (NASDAQ: MNTA, โMomentaโ or the โCompanyโ), a biotechnology company focused on discovering and developing novel...
By Peter Loftus and Colin Kellaher This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal...
By Colin Kellaher Johnson & Johnson on Wednesday said it agreed to buy Momenta Pharmaceuticals Inc. for about $6.5 billion, or $52.50 a share, in cash. The deal represents a roughly 70...
Johnson & Johnson to acquireย Momentaย for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momentaโs closing price on August 18, 2020 Momentaโs...
-- Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p<0.0001...
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals,ย Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to...
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease...
- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001) -ย ย ย ย - Nipocalimab induced a rapid and durable...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions